Citius Pharmaceuticals, Inc.
CTXR
$0.85
$0.000.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.80M | 7.17M | 7.49M | 7.91M | 8.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.44M | 8.79M | 11.26M | 10.04M | 11.05M |
| Operating Income | -8.44M | -8.79M | -11.26M | -10.04M | -11.05M |
| Income Before Tax | -8.48M | -8.94M | -11.25M | -10.02M | -10.93M |
| Income Tax Expenses | 264.20K | 264.20K | 264.20K | 264.20K | 144.00K |
| Earnings from Continuing Operations | -8.74M | -9.20M | -11.51M | -10.28M | -11.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 784.40K | 414.00K | 595.00K | 513.00K | 287.00K |
| Net Income | -7.96M | -8.79M | -10.92M | -9.77M | -10.79M |
| EBIT | -8.44M | -8.79M | -11.26M | -10.04M | -11.05M |
| EBITDA | -8.44M | -8.79M | -11.26M | -10.04M | -11.05M |
| EPS Basic | -0.46 | -0.80 | -1.27 | -1.30 | -1.59 |
| Normalized Basic EPS | -0.26 | -0.47 | -0.75 | -0.77 | -0.90 |
| EPS Diluted | -0.46 | -0.80 | -1.27 | -1.30 | -1.59 |
| Normalized Diluted EPS | -0.26 | -0.47 | -0.75 | -0.77 | -0.90 |
| Average Basic Shares Outstanding | 17.20M | 11.01M | 8.58M | 7.49M | 7.23M |
| Average Diluted Shares Outstanding | 17.20M | 11.01M | 8.58M | 7.49M | 7.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |